NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
60505-6230-04 | 60505-6230 | Paclitaxel | Paclitaxel protein-bound particles for injectable suspension (albumin-bound) | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Apr 1, 2022 | Apr 30, 2025 | In Use |
62332-0620-05 | 62332-0620 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 20, 2022 | In Use | |
46708-0620-05 | 46708-0620 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 20, 2022 | In Use | |
00703-3216-81 | 00703-3216 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 5, 2020 | In Use | |
63323-0763-16 | 63323-0763 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 20, 2009 | In Use | |
24979-0710-51 | 24979-0710 | Paclitaxel | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Apr 1, 2022 | May 31, 2025 | In Use |
00703-3216-01 | 00703-3216 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 25, 2020 | In Use | |
70860-0200-17 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 24, 2017 | Nov 30, 2024 | No Longer Used |
62332-0622-50 | 62332-0622 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 20, 2022 | In Use | |
00703-3213-01 | 00703-3213 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 7, 2020 | In Use | |
00480-3290-01 | 00480-3290 | Paclitaxel | Paclitaxel | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 2, 2024 | In Use | |
00703-3213-81 | 00703-3213 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 7, 2020 | In Use | |
70860-0215-66 | 70860-0215 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec 15, 2021 | Sep 30, 2024 | No Longer Used |
70860-0215-67 | 70860-0215 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec 15, 2021 | Nov 30, 2024 | No Longer Used |
72205-0061-01 | 72205-0061 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 26, 2020 | In Use | |
70860-0200-05 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 24, 2017 | Dec 31, 2024 | No Longer Used |
69539-0158-01 | 69539-0158 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 26, 2020 | In Use | |
23155-0884-31 | 23155-0884 | Paclitaxel | PACLITAXEL | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 31, 2023 | In Use | |
55390-0304-05 | 55390-0304 | Paclitaxel | Paclitaxel | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec 1, 2006 | Apr 30, 2013 | No Longer Used | |
72482-0100-12 | 72482-0100 | Pacritinib | Vonjo | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | JAK2, FLT3 | Oral | Feb 28, 2022 | In Use | |
00069-0486-03 | 00069-0486 | Palbociclib | Ibrance | 100.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Mar 30, 2020 | In Use | |
63539-0486-03 | 63539-0486 | palbociclib | Ibrance | 100.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Mar 30, 2020 | In Use | |
63539-0284-03 | 63539-0284 | palbociclib | Ibrance | 75.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Mar 30, 2020 | In Use | |
00069-0284-03 | 00069-0284 | Palbociclib | Ibrance | 75.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Mar 30, 2020 | In Use | |
00069-0189-21 | 00069-0189 | Palbociclib | Ibrance | 125.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Feb 3, 2015 | In Use |
Found 11465 results — Export these results